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PURPOSE. Antioxidant supplements may reduce age-related
macular degeneration (AMD) progression. The macular carot-
enoids are of particular interest because of their biochemical,
optical, and anatomic properties. This classic twin study was
designed to determine the heritability of macular pigment (MP)
augmentation in response to supplemental lutein (L) and
zeaxanthin (Z).
METHODS. A total of 322 healthy female twin volunteers, aged
16–50 years (mean 40 6 8.7) was enrolled in a prospective,
nonrandomized supplement study. Macular pigment optical
density (MPOD) measurements using two techniques (2-
wavelength fundus autofluorescence [AF] and heterochromat-
ic flicker photometry [HFP]), and serum concentrations of L
and Z, were recorded at baseline, and at 3 and 6 months
following daily supplementation with 18 mg L and 2.4 mg Z for
a study period of 6 months.
RESULTS. At baseline, mean MPOD was 0.44 density units (SD
0.21, range 0.04–1.25) using HFP, and 0.41 density units (SD
0.15) using AF. Serum L and Z levels were raised significantly
from baseline following 3 months’ supplementation (mean
increase 223% and 633%, respectively, P < 0.0001 for both),
with no MPOD increase. After 6 months’ supplementation, a
small increase in MPOD was seen (mean increase 0.025 6
0.16, P¼ 0.02, using HFP). Subdivision of baseline MPOD into
quartiles revealed that baseline levels made no difference to
the treatment effect. Genetic factors explained 27% (95%
confidence interval [CI] 7–45) of the variation in MPOD
response. Distribution profiles of macular pigment did not
change in response to supplementation.
CONCLUSIONS. MPOD response to supplemental L and Z for a
period of 6 months was small (an increase over baseline of
5.7% and 3.7%, measured using HFP and AF, respectively), and
was moderately heritable. Further study is indicated to
investigate the functional and clinical impact of supplementa-
tion with the macular carotenoids. (Invest Ophthalmol Vis Sci.
2012;53:4963–4968) DOI:10.1167/iovs.12-9618
Age-related macular degeneration (AMD) is the leading causeof blindness among the elderly in industrialized countries,
and oxidative stress is likely to contribute to its pathogene-
sis.1,2 Macular pigment (MP) represents an accumulation in the
central retina of three carotenoids, lutein (L), zeaxanthin (Z),
and meso-zeaxanthin (m-Z), which give the macula its
characteristic yellow color.3 There is a biologically plausible
rationale for the protective role of MP in the retina: it absorbs
blue light, thus reducing light-induced oxidative stress, and it
has direct antioxidant properties by quenching reactive oxygen
species.1,4,5 Furthermore, there is a growing body of evidence
that the blue-light filtering properties of this pigment optimize
contrast sensitivity and protect against glare disability because
of the impact on chromatic aberration and light scatter,6,7
although this has been questioned.8 L and Z cannot be
synthesized de novo in mammals, and are entirely of dietary
origin, predominantly derived from fruits and vegetables.9
However, m-Z is not found in a typical diet, and is the result of
conversion from retinal L.10 Given the potentially beneficial
impact of appropriate supplementation on AMD prevalence
and progression, there is considerable interest among research-
ers, clinicians, and the general public regarding the role of
supplementation with the macular carotenoids.
Several clinical studies have investigated whether MP
density can be modified either through dietary modification
(for example, consumption of spinach/corn) or supplementa-
tion. Supplement studies in healthy subjects and subjects with
retinal degeneration generally have been small (n ¼ 2–108,
reviewed by Connolly et al.11), and many have not been
randomized, placebo-controlled in design. Their results suggest
that there is considerable variability in the MP response to
dietary modification/supplementation, ranging from ‘‘non-
responders’’ to reports of increases up to 40%.12 Given this
variation, the purpose of our study was to determine to what
extent variation in response is determined by genes or
environment, by establishing a classic twin study to estimate
the heritability of MP response to supplemental L and Z.
METHODS
We recruited 322 healthy, female twin volunteers, aged 16–50 years
(mean 39 6 8.7 years), from the TwinsUK adult registry held at St.
Thomas’ Hospital, London,13 which enrolls twins from the general
population through local and national media campaigns. Power
calculations before starting the study suggested a sample size of 70
monozygotic (MZ) and 70 dizygotic (DZ) twin pairs would detect a
heritability change in macular pigment optical density (MPOD) of 30%
From the 1Department of Twin Research and Genetic Epidemi-
ology, King’s College London, St. Thomas’ Hospital campus, London,
United Kingdom; the 2Department of Ophthalmology, King’s College
London, St. Thomas’ Hospital, London; United Kingdom; the
3Department of Ophthalmology, University of Minnesota, Minneap-
olis, Minnesota; the 4Macular Pigment Research Group, Waterford
Institute of Technology, Waterford, Ireland; and the 5International
Centre for Eye Health, London School of Hygiene and Tropical
Medicine, London, United Kingdom.
Supported by Wellcome Trust and by a Research to Prevent
Blindness unrestricted grant to University of Minnesota (FJVK).
Submitted for publication February 2, 2012; revised May 18,
2012; accepted June 10, 2012.
Disclosure: C.J. Hammond, None; S.H.M. Liew, None; F.J.
Van Kuijk, Springfield (F); S. Beatty, None; J.M. Nolan, None; T.D.
Spector, None; C.E. Gilbert, None
Corresponding author: Christopher J. Hammond, Department
of Twin Research and Genetic Epidemiology, King’s College London,
St. Thomas’ Hospital campus, Westminster Bridge Road, London,
UK; chris.hammond@kcl.ac.uk.
Investigative Ophthalmology & Visual Science, July 2012, Vol. 53, No. 8
Copyright 2012 The Association for Research in Vision and Ophthalmology, Inc. 4963
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/933262/ on 10/09/2017
from baseline; we aimed to recruit 80 MZ and 80 DZ pairs to allow for
drop-outs. Informed consent was obtained from each volunteer and,
following local ethics committee approval, the research procedures
followed the tenets of the Declaration of Helsinki. All subjects were
female twins with no ocular pathology (mean 6 SD logMAR visual
acuity 0.0 6 0.1 [equivalent to 6/6 Snellen acuity]) or gastrointestinal
disease. Details of the study population have been reported previous-
ly.14
Zygosity was determined by a standardized questionnaire, which
has been shown to be at least 95% accurate.15 In cases when there was
any doubt concerning zygosity, DNA analysis of short tandem-repeat
polymorphisms using the AmpF1 STR Profiler kit (PE Applied
Biosystems, Foster City, CA) was performed. DNA analysis was
performed in 68 twin pairs (45%).
All subjects were asked to take a daily MP supplement with food (3
tablets of ‘‘Macuvite’’ [Springfield, Oud-Beijerland, The Netherlands],
consisting of 18 mg lutein [in its free form] and 2.4 mg of zeaxanthin
[derived from marigold flowers and microalgae]) for 6 months.
Subjects were asked to continue their normal diet, and compliance
was assessed at 3 and 6 months by pill counts. We calculated the
number of supplement tablets taken, as a percentage of the expected
number of pills that would have been taken if they had complied with
the prescribed dosage.
MP, Dietary, and Serum Carotenoid Measurement
MPOD was measured by one investigator at baseline, and at 3 and 6
months following commencement of supplementation using a
psychophysical method (heterochromatic flicker photometry [HFP]),
and an imaging method (2-wavelength fundus autofluorescence [AF]).
These methods, and their validity and repeatability, have been
described previously.14
The apparatus used in our study for HFP measurements was the
Maculometer. This instrument uses light emitting diodes, which emit
near-monochromatic light.16 The subject views the foveal target at a
distance of 330 mm, which subtends a diameter of one degree at the
eye. For the parafoveal reference match, where it is assumed there is
no MP, the test field is an annulus of 10 degrees (inner diameter) with a
width of one degree. The Maculometer uses central fixation for the
parafoveal match, when the foveal test field is switched to a dim red
spot to provide a fixation target. Thus, the subject always is fixating on
the central one-degree field.
HFP is a psychophysical test that uses MP’s absorption and spatial
distribution characteristics to calculate the optical density of this
pigment.17,18 The test field flickers between a light that has a
wavelength close to the peak absorption of MP (blue light, kmax ¼
468 nm) and a longer wavelength reference light, which has a
wavelength close to minimum or zero absorption by MP (green light,
kmax ¼ 535 nm). It is assumed that the presence of MP decreases the
spectral sensitivity of macular photoreceptors to blue light. During this
test, the green reference light remains at a fixed luminance and the
subject, using a dial, can vary the blue light intensity. The amount of
blue light luminance required to achieve matching luminance with the
green light will be a measure of MPOD. When the luminances of the
blue and green light are matched closely, the subject will perceive
minimum flicker. A minimum flicker match is made in the following 2
locations: when the retinal image of the target field lies on the fovea
and when the retinal image of the target field lies in the parafovea,
where there is minimal or no MP. The logarithm of the ratio of the blue
luminosity for the foveal match to the blue luminosity of the parafoveal
reference match gives a measure of the MPOD. Following 2 ‘‘practice’’
matches, five foveal readings were obtained, followed by 5 parafoveal
readings for each subject at each visit. HFP was performed in both eyes,
and the first eye to be tested alternated with each subsequent twin pair
tested.
On completion of the HFP test, subjects’ eyes were dilated and the
AF test for MPOD was carried out in a darkened room. This technique
takes advantage of the autofluorescence characteristic of lipofuscin,
which is found in the RPE and has been described previously in
detail.19 As the MP absorption range (400–550 nm) is within the
excitation range of lipofuscin,20 absorption of light by MP before it
reaches the RPE layer will cause attenuation of the AF. The principle of
this technique is that the amount of light absorption by the MP is
related strongly to the amount of MP within the retina and, therefore,
can provide a measure of MPOD. Two different wavelengths of light
are used to stimulate AF, one that is well absorbed by MP and one that is
absorbed minimally by MP, to provide reference values for AF emitted
in the absence of MP, as this is not uniform across the field.21
Therefore, a comparison of AF intensity recorded at the 2 different
wavelengths allows quantification of MPOD.
A modified confocal scanning laser ophthalmoscope (Heidelberg
Engineering, Heidelberg, Germany) was used to obtain high resolution,
20-degree field AF images at 488 nm (blue) and 514 nm (green). The
gain of the instrument was fixed at the same intensity for all subjects
throughout the entire study. Each day MP measurements were made
the instrument was allowed to warm up for 1 hour before a subject was
tested. A software program has been developed that creates an MPOD
map, generated by using a gray scale index of intensity and by digital
subtraction of the AF images taken at the 2 different wavelengths.22
Using the AF method, the MPOD at 0.5 degrees eccentricity was
measured. The total MP quantity (proportional to the area under the
curve of MP profile, in a10-degree diameter area, centered on fovea)
and the quantity of MP in the central area, where MP has the highest
concentration (one-degree diameter disc area), also were calculated. As
high MPOD interocular symmetry is well established,14 we used
readings from subjects’ right eyes.
Average daily dietary L and Z intake (mg/day) was evaluated at
baseline using a validated food frequency questionnaire (FFQ),
developed by the Scottish Collaborative Group,23,24 where subjects
were asked to recall their average food consumption of specific foods
over the preceding 3 months. The FFQs were scanned and verified at
the Medical Research Council Human Nutrition Research, Cambridge,
UK. Blood samples were obtained on the same day as MPOD was
measured, at baseline, and at 3 months. Serum carotenoid levels were
measured using reverse phase high performance liquid chromatogra-
phy at the Waterford Institute of Technology.11
Data Analysis
Data analysis was performed using the STATA computer statistics
package (Version 8 SE; StataCorp, College Station, TX). Wilcoxon
signed rank tests were used to test the statistical significance of the
change in MPOD between visits. Maximum likelihood modeling,
using the Mx program,25 was performed to estimate the heritability of
MP response to supplementation.26 This method is based on
comparing the covariances of a measured trait between MZ and DZ
twins. The observed phenotypic variance can be divided into additive
genetic (A), dominant genetic (D), common environmental (C), and
unique environmental (E) components. Heritability is defined as the
proportion of the phenotypic variation attributable to genetic factors,
and is given by the equation, h2 ¼ ðA þ DÞ=ðAþ D þ C þ EÞ. The
Akaike Information Criterion (AIC) was used to determine the best
fitting model, with the lowest AIC suggesting the best fit.
Many MP studies have divided subjects into ‘‘responders’’ and ‘‘non-
responders.’’ For a quantitative trait, this probably is inappropriate, as
there likely is to be a range of responses. However, it is of interest to
examine whether subjects with lower levels (due to dietary or genetic
factors) might have a different response to those with highest levels
(who might have reached a saturation threshold). When looking for a
change from baseline, as in our study, analyzing the data to check for
regression to the mean is necessary. Regression to the mean refers to
the widespread statistical phenomenon that those with extreme scores
of a biologic measure subject to variation at any measurement time
point will, for purely statistical reasons, have a greater chance of less
extreme scores at the next time point they are tested. Therefore, a
subject who has a below average baseline MPOD is more likely to have
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a higher score (nearer the population mean) at the following
measurement point in time, and vice versa for those with ‘‘high’’
baseline MPOD. This decrease (or increase) can be attributed
mistakenly to a treatment effect when it actually has occurred due to
chance.27,28 Statistical modeling using analysis of covariance (ANCO-
VA) was used to examine regression effects.
RESULTS
Of the 322 subjects enrolled 290 completed the 3-month visit
(90%) and 264 completed the 6-month visit (82%), with no
differences between those completing and not completing the
supplement period in terms of baseline MPOD. The mean
compliance with L/Z supplementation, measured by pill count,
was 89.8% 6 13.5% at 3 months (number of observations ¼
260) and 90.5% 6 11.9% during the second 3-month interval
(number of observations¼ 240). There were no adverse events
associated with the supplements.
The mean dietary consumption of L and Z, before
commencing supplementation, was 1.696 1.48 mg/day (range
0.18–11.04). At baseline, MPOD values exhibited a normal
distribution using the HFP method of assessment (skew test for
normality, P ¼ 0.13) and a near normal distribution using AF
(although this was not statistically normal).29 Mean MPOD, MP
volume, and serum carotenoid concentration values, at
baseline and following supplementation, are given in the
Table. There were 83 MZ twin pairs (mean age 39.9 6 8.76
years) and 78 DZ twin pairs (mean age 40.6 6 8.46 years)
included in the study, and mean baseline MPOD was 0.42 6
0.21 (measured by HFP) and 0.40 6 0.15 (AF) for MZ twins,
and 0.46 6 0.21 (HFP) and 0.42 6 0.15 (AF) for DZ twins, not
significantly different (P > 0.05) between zygosities. Mean 6
SD baseline serum L was 0.12 6 0.05 lg/mL, the same for MZ
and DZ twins.
Overall, for the entire cohort, serum levels of L and Z
showed a significant increase after 3 months of supplementa-
tion, with a mean increase of 223% and 633% from baseline for
L and Z, respectively (P ¼ < 0.001 for both). However, there
was no significant increase in MPOD (HFP method P¼0.75, AF
method P ¼ 0.70) following 3 months of supplementation.
Following 6 months of supplementation, an increase in MPOD
from baseline was seen (mean increase 6 SD HFP 0.025 6
0.16, P ¼ 0.02; AF 0.015 6 0.058, P < 0.001), which was
statistically significant and represented a mean MPOD rise of
5.7% (HFP) and 3.7% (AF, Fig. 1). Analyzing the MP volume
results revealed the same trend with no difference in total or
central MP volume at 3 months (P ¼ 0.22 total, P ¼ 0.11
central), but a statistically significant increase (1.25% rise in
total MP, 1.45% rise in central) after 6 months of supplemen-
tation (P¼ 0.01 total, P < 0.001 central, Fig. 2). There was no
change in MP distribution profile, which is heritable.14
The correlation coefficients within MZ twin pairs for
change in MPOD were higher than DZ correlations, although
these generally were low at r ¼ 0.32 and r ¼ 0.11 for MZ and
DZ twins, respectively, using the AF method, and only r¼ 0.13
and r ¼ 0.04, respectively, when using the HFP method.
Genetic modeling suggested the heritability of MPOD response
measured with AF to supplementation was 0.27 (95%
confidence interval [CI] 0.07–0.45). The residual variance
was explained by environmental effects (0.73, 95% CI 0.55–
0.93); this includes measurement error. Modelling using HFP
data found no significant genetic influence on MPOD response.
There was no significant difference in supplementation
effect between the highest and lowest quartiles of baseline
MPOD, after adjusting for regression to the mean (P¼0.629 for
quartile 4 vs. 1). The Macuvite capsules used were analyzed in
FIGURE 1. Box plots illustrating macular pigment levels (measured by
HFP) at baseline, 3-months (visit 2), and 6-months (visit 3) following L/
Z supplementation.
FIGURE 2. Serum L and Z results at baseline (visit 1) and 3-months
(visit 2).
TABLE. Mean (SD) MPOD, MP Volume, and Serum Carotenoid Measurements at Baseline and 3 and 6 Months following L/Z Supplementation
Baseline 3 Months 6 Months
MPOD measured by HFP (DU) 0.44 (0.21) n ¼ 301 0.43 (0.19) n ¼ 251 0.47 (0.19) n ¼ 245
MPOD measured by AF (DU) 0.41 (0.15) n ¼ 321 0.40 (0.16) n ¼ 290 0.43 (0.16) n ¼ 264
Central MP quantity 265.9 (92.4) 259.7 (97.2) 272.5 (94.0)
Total MP quantity 3788.6 (2059.2) 3614.1 (1602.5) 3890.9 (1653.3)
Serum L (lg/mL) 0.13 (0.06) 0.29 (0.16)
Serum Z (lg/mL) 0.03 (0.02) 0.19 (0.09)
DU, density units.
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an independent laboratory that quantified the contents of L at
5.28 mg and Z at 0.91 mg per capsule, suggesting the actual
daily dosages were 15.9 and 2.7 mg, respectively, similar to the
intended doses of 18 mg of L and 2.4 mg of Z. (Hogerhuis,
personal communication 2009).
DISCUSSION
We designed a study to investigate heritability of response, in
terms of MPOD, to supplementation with its constituent
carotenoids (L and Z). Heritability can be defined as the
proportion of phenotypic variation attributable to genetic
background, and is determined best by a classical twin study
with its inherent capacity to assign relative contributions of
genes and environment to a given variable following a
comparative analysis of MZ and DZ twins. In this context, we
report that 27% of variation in response, in terms of MPOD
augmentation, is attributable to genetic factors. However, these
findings should be interpreted with full appreciation of the
modest, yet statistically significant, rise in MPOD observed
here, reflected in the wide CIs of the heritability (0.07–0.45).
Although MP is entirely of dietary origin, it is neither surprising
nor counterintuitive that tissue uptake and/or concentrations
of its constituent carotenoids are determined by genetic
background, as is the case with vitamin C.29 Indeed, our
research group has demonstrated previously heritability
estimates of 0.67–0.85 for MPOD in the baseline cross-sectional
component of the current study.14
The accumulation of MP in the central retina depends on
the journey of its constituent carotenoids from foodstuff to
target tissue and, therefore, depends on a wide array of
processes, including digestion, absorption, transport in serum,
and ultimately, capture by and stabilization within the retina.
As a consequence, genetic background could exert its
influence on MPOD response to supplementation through
any number of mechanisms known to be subject to genetic
influence, including lipoprotein and/or xanthophyll-binding
protein profile, and concentrations of antioxidant enzymes
within the retina.30–32
The possibility that supplementation with the macular
carotenoids is beneficial has prompted their widespread use in
recent years,33 and is based on the rationale that MP is a filter
of short wavelength (blue) visible light at a pre-receptoral level,
with consequences for vision and for generation of reactive
oxygen intermediates (ROIs) at the central retina. This role
might confer protection against AMD development and/or
progression, but because of the difficulties inherent in testing
such a hypothesis (involving long-term study of the effects of
cumulative oxidative damage), current evidence is based
largely on cross-sectional studies (with their inherent inability
to comment upon cause and effect) and a few clinical trials
with small numbers of subjects followed for short periods of
time. The extensive literature in this regard recently has been
reviewed extensively, and can be summarized as follows: most
studies demonstrate a relative lack of MP in association with
risk-factors for AMD, and the few reported clinical trials
indicated a benefit is association with supplemental L and Z.34
Level 1 evidence that supplementation with antioxidants is
beneficial in AMD does exist in the form of the Age Related Eye
Disease Study (AREDS),35 but this evidence does not extend to
the macular carotenoids, which is the subject of AREDS II.36
In any case, any beneficial effect of supplementation with
the macular carotenoids rests on the premise that such
supplementation does, indeed, result in augmentation of MP.
In this regard, our study has revealed some interesting and
clinically important findings. To our knowledge, our study
represents the largest investigation of supplemental L and Z in
a healthy population, and resulted in a modest, albeit
statistically significant, increase in MPOD of only 4–5%,
reflected in a mean response of only 0.02 density units,
following 6 months of supplementation. Furthermore, this
observed MP augmentation of questionable clinical importance
was observed despite increases in serum concentrations of L
and Z of 233% and 633%, respectively. The similarity of effect
in subjects, whether they were in the lowest or highest
quartile, suggests the findings are applicable to all subjects,
whatever their baseline MPOD, and that the ‘‘healthy’’
population does not have a saturation level. The rise in MPOD
(using AF) at 6 months was related only weakly to the serum L
levels measured at 3 months (correlation coefficient r¼0.14, P
¼ 0.03).
Previous studies, sometimes following exclusion of ‘‘retinal
non-responders,’’ typically have reported larger increases in
MP (4%–30%) and in serum concentrations of its constituent
carotenoids (400%–1000%) following supplementation with L
and/or Z.11 Our 2-fold and 6-fold increase in serum L and Z
were approximately half of the 3.7-fold and 13-fold increases in
the Lutein Xanthophyll Eye Accumulation (LUXEA) study of 92
subjects, also using free L, which demonstrated a similar, small,
increase in MPOD. Although 6 months of MPOD data were not
presented, supplementation for 12 months increased MPOD by
14–15%, and graphs presented suggest a linear increase over
the 12 months, which can be interpreted as a rise of ~7% at 6
months).37 The LUNA study, which supplemented 108 patients
with features of AMD, found an approximately 4-fold increase
in serum L and a mean MPOD increase of 12% following 6
months of supplementation with Ocuvite Lutein, which
contains 12 mg L provided as an ester together with co-
antioxidants (vitamin C, E, Zn, and selenium).38 However, it
should be noted that the control group in this study also
showed a raised MPOD, and the analysis did not take this into
account. The variable MPOD augmentation with supplemen-
tation observed in this and other studies highlights the
complexity of the physiology of antioxidants, such as L and Z.
There are several possible explanations of our poorer
response. First, our study was comprised of women, and some
studies have found lower responses in women compared to
men.39–41 Second, there may have been degradation of these
compounds where participants were given a three-month
supply, a problem identified recently,11 although the capsule
concentrations reported here were measured from the same
batch at the conclusion of the study. Concentrations of
constituent components of many supplements marketed for
the purpose of enhancing eye health have been described as
inappropriate,42 and disparities between claimed and actual
composition of antioxidant supplements is a subject worthy of
study. The third reason may relate to bioavailability and optimal
formulation of L/Z. The formulation used in our study
consisted of free lutein (FloraGlo), and zeaxanthin from
marigold and microalgae in a capsule (cellulose, magnesium
stearate, Macuvite). It may be that the esterified form of L is
more bioavailable.43 It also is known that the bioavailability of
L and Z is influenced by interactions with other dietary
constituents (e.g., increased bioavailability when associated
with lipid matrix, such as in egg yolks).44
The fourth reason may relate to m-Z. We cannot measure
relative levels of carotenoids, but m-Z is the dominant
carotenoid at the center of the fovea and is the result of
conversion of retinal L (but not Z).10 Some individuals might
lack the capacity to convert retinal L to m-Z and, therefore,
‘‘nonresponders’’ might not respond to supplemental L at 0.5
degrees (the eccentricity measured and reported here and in
most studies), which might be influenced by genetic back-
ground. We did not exclude ‘‘retinal nonresponders’’ as other
studies have, as we wanted to explore whether response (or
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lack of it) is determined by genetic factors, and public health
measures to recommend generalized supplementation with L
and Z must be based on evidence from unselected populations.
Approximately 12% of the population has an ‘‘atypical’’ central
dip in their spatial profile of MP associated with established
risk-factors for AMD, such as smoking and increasing age, and
this may reflect an inability to convert retinal L to m-Z.45 We
found no change in the MPOD distribution profiles after
supplementation with L and Z, but it has been reported that
supplementation with all three macular carotenoids (including
m-Z) results in augmentation of MPOD in all subjects and
normalization of these ‘‘atypical’’ profiles.45,46 Meaningful
comment upon the magnitude of response to supplementation
with the macular carotenoids requires a placebo-controlled
group, which was not included in the design of the current
investigation because our primary objective was to determine
the heritability of the response to supplementation of L and Z.
The MPOD values from our study population are compa-
rable to other studies of normal subjects47,48 and twins have
been shown to be comparable to singletons in complex
traits.49 The results were not altered when twin relationships
were taken into account, either by randomly dropping one of
each twin pair or using generalized estimating equations.
Although several large studies have not shown a significant sex
difference in MP levels,19,50–52 it should be noted that the mean
MPOD in this female, volunteer group is higher than reported
in other studies that have shown that females have lower
MPOD than males.16,39,53 It is possible that this twin, volunteer
group may have healthier lifestyles and diets compared to the
general population or other singleton volunteer groups. The
average daily L/Z consumption in this volunteer group (1.69 6
1.48) is comparable to the female volunteers in the study of
Nolan et al.54 (1.61 6 1.06), which used the same FFQ. The
normal Western daily diet has been reported to contain
approximately 1.3 to 3 mg of L and Z55; however, directly
comparing dietary intakes, assessed using different food
frequency questionnaires and carotenoid databases, may not
be completely accurate.
In conclusion, MPOD response to 6 months of supplemen-
tation with L and Z in an unselected, healthy twin volunteer
sample was moderately heritable, but in our study the increase
in MPOD was small and of questionable clinical significance.
The clinical and functional impact of supplementation with the
macular carotenoids requires further study.
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